You are here

Home › For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies › For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies

For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies

Primary tabs

For older patients, Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief --two new studies

Tue, 2024-11-12 10:44 — mike kraft
Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find Overall, the risk of developing 28 out of 36 long-COVID symptoms lessened when vaccines were effective. CIDRAP

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Benefit seen only in older patients

 

Country / Region Tags: 
Europe
Global
United States
General Topic Tags: 
COVID-19
Treatments
Data
Demographics
Disease
Health
Public Health
Research
Problem, Solution, SitRep, or ?: 
Analysis
Situation Report
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.418 seconds.